

## News Release

July 26, 2021  
Carna Biosciences, Inc.

### **Carna Announces Completion of Dosing in Phase 1 SAD Study of AS-1763**

Carna Biosciences, a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative therapies to treat serious unmet medical needs, announces that the dosing of the subjects in its Phase 1 single ascending dose (SAD) study has been completed. The Phase 1 clinical study of AS-1763 is a randomized, double-blind, placebo controlled, oral single ascending dose study in healthy male and female adult subjects and the first subject was dosed with AS-1763 on April 27(CEST).

AS-1763 is an investigational small molecule drug designed to non-covalently inhibit Bruton's tyrosine kinase (BTK) in a highly selective manner. According to the preclinical data, the compound is capable of potently inhibiting both wild and C481S mutant BTK, and AS-1763 is currently under development for treating patients with chronic lymphocytic leukemia (CLL) and other B cell malignancies with acquired resistance to covalent BTK inhibitors.

Carna is planning to initiate a Phase 1b clinical study in patients in the U.S. based on the results of the SAD study.

#### About AS-1763

AS-1763 is a highly selective, orally bioavailable, non-covalent inhibitor of both the wild type and C481S mutant Bruton's tyrosine kinases (BTK) for the treatment of chronic lymphocytic leukemia (CLL) and other B cell malignancies. First generation covalent BTK inhibitors including ibrutinib are key therapeutic options for patients with B cell malignancies. However, patients are reported to develop resistance during the treatment due to substitution of cysteine residue at 481 position with serine (C481S mutation) in BTK, which prevents the covalent binding of the first generation irreversible BTK inhibitors. In in vitro experiments, AS-1763 significantly abrogates cell proliferation in both wild type and C481S mutant BTK lymphoma cells, strongly suggesting AS-1763 will be a new therapeutic option for treating patients with B cell malignancies both having wild type and C481S mutation in BTK.

Contact:

Corporate Planning

Carna Biosciences, Inc.

TEL: +81-78-302-7075

<https://www.carnabio.com/english/>